JP2023550462A5 - - Google Patents

Info

Publication number
JP2023550462A5
JP2023550462A5 JP2023530591A JP2023530591A JP2023550462A5 JP 2023550462 A5 JP2023550462 A5 JP 2023550462A5 JP 2023530591 A JP2023530591 A JP 2023530591A JP 2023530591 A JP2023530591 A JP 2023530591A JP 2023550462 A5 JP2023550462 A5 JP 2023550462A5
Authority
JP
Japan
Prior art keywords
composition according
radiopharmaceutical composition
cancer
her3
radionuclide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023530591A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023550462A (ja
Filing date
Publication date
Priority claimed from PCT/US2021/056259 external-priority patent/WO2022087416A1/en
Application filed filed Critical
Priority claimed from PCT/US2021/060370 external-priority patent/WO2022109404A1/en
Publication of JP2023550462A publication Critical patent/JP2023550462A/ja
Publication of JP2023550462A5 publication Critical patent/JP2023550462A5/ja
Pending legal-status Critical Current

Links

JP2023530591A 2020-11-20 2021-11-22 固形がんの治療のためのher3放射免疫治療薬 Pending JP2023550462A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US202063116225P 2020-11-20 2020-11-20
US63/116,225 2020-11-20
US202063118181P 2020-11-25 2020-11-25
US63/118,181 2020-11-25
US202163226699P 2021-07-28 2021-07-28
US63/226,699 2021-07-28
US202163250725P 2021-09-30 2021-09-30
US63/250,725 2021-09-30
PCT/US2021/056259 WO2022087416A1 (en) 2020-10-22 2021-10-22 Combination radioimmunotherapy and cd47 blockade in the treatment of cancer
USPCT/US2021/056259 2021-10-22
PCT/US2021/060370 WO2022109404A1 (en) 2020-11-20 2021-11-22 Her3 radioimmunotherapy for the treatment of solid cancers

Publications (2)

Publication Number Publication Date
JP2023550462A JP2023550462A (ja) 2023-12-01
JP2023550462A5 true JP2023550462A5 (https=) 2024-11-29

Family

ID=81709768

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023530591A Pending JP2023550462A (ja) 2020-11-20 2021-11-22 固形がんの治療のためのher3放射免疫治療薬

Country Status (8)

Country Link
EP (1) EP4247430A4 (https=)
JP (1) JP2023550462A (https=)
KR (1) KR20230128271A (https=)
AU (1) AU2021382717A1 (https=)
CA (1) CA3199259A1 (https=)
IL (1) IL303030A (https=)
MX (1) MX2023005940A (https=)
WO (1) WO2022109404A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022087416A1 (en) * 2020-10-22 2022-04-28 Actinium Pharmaceuticals, Inc. Combination radioimmunotherapy and cd47 blockade in the treatment of cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6683162B2 (en) * 2000-09-15 2004-01-27 Sloan Kettering Institute Of Cancer Research Targeted alpha particle therapy using actinium-255 conjugates
AR056857A1 (es) * 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
EA201200195A1 (ru) * 2009-08-21 2012-12-28 Мерримаск Фармасьютикалс, Инк. АНТИТЕЛА ПРОТИВ ЭКТОДОМЕНА ErbB3 И ИХ ПРИМЕНЕНИЕ
WO2012018404A2 (en) * 2010-08-06 2012-02-09 U3 Pharma Gmbh Use of her3 binding agents in prostate treatment
EP3322735A4 (en) * 2015-07-15 2019-03-13 Zymeworks Inc. ACTIVE CONJUGATED BIS-SPECIFIC ANTIGEN-BONDING CONSTRUCTS
WO2020132672A1 (en) * 2018-12-21 2020-06-25 Actinium Pharmaceuticals, Inc. Combination of radioimmunotherapy and immune checkpoint therapy in the treatment of cancer

Similar Documents

Publication Publication Date Title
AU709694B2 (en) Methods of treating colon cancer utilizing tumor-specific antibodies
US9849176B2 (en) RS7 antibodies
CN101972478B (zh) 抗体治疗
CN100548374C (zh) 用ⅲ类抗cea单克隆抗体和治疗剂进行联合治疗
AU2019234468B2 (en) Bispecific binding agents and uses thereof
JP2006521286A5 (https=)
JP2024056687A (ja) キレート化された放射性核種に対する抗体
CN106573983B (zh) 用于在癌症的预防和/或治疗中使用的放射性标记的抗体片段
DeNardo Radioimmunodetection and therapy of breast cancer
JP7582867B2 (ja) キレート化された放射性核種に対する抗体および除去剤
JP2023550462A5 (https=)
EP4251214A2 (en) Methods for treating cancer using combinations of epigenetic therapies and radioconjugate targeting agents
JP2022521773A5 (https=)
JP2023518818A5 (https=)
JP2024523438A5 (https=)
JP2023546277A5 (https=)
JP2001505203A (ja) 抗原a33に結合するヒト化抗体を用いた新形成の治療方法
JPWO2017061602A1 (ja) Cd147分子に特異的に結合する抗体およびその利用
WO2025089383A1 (ja) 225Ac標識抗CDH3抗体
Longo Monoclonal Antibodies in Cancer Treatment
HK1139316B (en) Combination therapy with class iii anti-cea monoclonal antibodies and therapeutic agents
Koppe Surgery and radioimmunotherapy in peritoneal carcinomatosis of colorectal origin.
HK1139316A (en) Combination therapy with class iii anti-cea monoclonal antibodies and therapeutic agents
BR112017001782B1 (pt) Domínio variável de cadeia pesada radiomarcado derivado de anticorpo de cadeia pesada (vhh), ou um fragmento funcional do mesmo, seu uso, e composição farmacêutica
HK1125030B (en) Rs7 antibodies